Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA)...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/10/10/342 |
| _version_ | 1797712050892308480 |
|---|---|
| author | Babak Nami Hamid Maadi Zhixiang Wang |
| author_facet | Babak Nami Hamid Maadi Zhixiang Wang |
| author_sort | Babak Nami |
| collection | DOAJ |
| description | Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA) to use as adjuvant therapy in combination with docetaxel to treat metastatic HER2-positive breast cancer. Adding the monoclonal antibodies to treatment regimen has changed the paradigm for treatment of HER2-positive breast cancer. Despite improving outcomes, the percentage of the patients who benefit from the treatment is still low. Continued research and development of novel agents and strategies of drug combinations is needed. A thorough understanding of the molecular mechanisms underlying the action and synergism of trastuzumab and pertuzumab is essential for moving forward to achieve high efficacy in treating HER2-positive breast cancer. This review examined and analyzed findings and hypotheses regarding the action and synergism of trastuzumab and pertuzumab and proposed a model of synergism based on available information. |
| first_indexed | 2024-03-12T07:15:11Z |
| format | Article |
| id | doaj.art-50807f70a271476a9df9814437d3f73c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T07:15:11Z |
| publishDate | 2018-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-50807f70a271476a9df9814437d3f73c2023-09-02T22:49:12ZengMDPI AGCancers2072-66942018-09-01101034210.3390/cancers10100342cancers10100342Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast CancerBabak Nami0Hamid Maadi1Zhixiang Wang2Signal Transduction Research Group, Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, CanadaSignal Transduction Research Group, Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, CanadaSignal Transduction Research Group, Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, CanadaHuman epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA) to use as adjuvant therapy in combination with docetaxel to treat metastatic HER2-positive breast cancer. Adding the monoclonal antibodies to treatment regimen has changed the paradigm for treatment of HER2-positive breast cancer. Despite improving outcomes, the percentage of the patients who benefit from the treatment is still low. Continued research and development of novel agents and strategies of drug combinations is needed. A thorough understanding of the molecular mechanisms underlying the action and synergism of trastuzumab and pertuzumab is essential for moving forward to achieve high efficacy in treating HER2-positive breast cancer. This review examined and analyzed findings and hypotheses regarding the action and synergism of trastuzumab and pertuzumab and proposed a model of synergism based on available information.http://www.mdpi.com/2072-6694/10/10/342trastuzumabpertuzumabbreast cancerHER2HER family receptorsmechanismssynergism |
| spellingShingle | Babak Nami Hamid Maadi Zhixiang Wang Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer Cancers trastuzumab pertuzumab breast cancer HER2 HER family receptors mechanisms synergism |
| title | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer |
| title_full | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer |
| title_fullStr | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer |
| title_full_unstemmed | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer |
| title_short | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer |
| title_sort | mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting her2 positive breast cancer |
| topic | trastuzumab pertuzumab breast cancer HER2 HER family receptors mechanisms synergism |
| url | http://www.mdpi.com/2072-6694/10/10/342 |
| work_keys_str_mv | AT babaknami mechanismsunderlyingtheactionandsynergismoftrastuzumabandpertuzumabintargetingher2positivebreastcancer AT hamidmaadi mechanismsunderlyingtheactionandsynergismoftrastuzumabandpertuzumabintargetingher2positivebreastcancer AT zhixiangwang mechanismsunderlyingtheactionandsynergismoftrastuzumabandpertuzumabintargetingher2positivebreastcancer |